Table 3 Plasma Renalase, dopamine, and norepinephrine levels in patients with chronic kidney disease - hemodialyzed (before and after treatment - HD A, HD B), peritoneal dialysis (PD) treated conservatively (CKD), before and after kidney transplantation (TE A TE B), and in the control group (NK) (mean ± OS, median - lower and upper quartile). P* Kruskal-Wallis rank ANOVA analysis of Renalase concentration across study groups
Parameters | Group of patients | Descriptive statistics | p* |
|---|---|---|---|
Renalase [ng/mL] | Before Hemodialysis (HD A) | 5709 ± 7930 1459 (865; 11 045) | <0,001 |
After Hemodialysis (HD B) | 7944 ± 7285 5340 (2085; 13 930) | ||
Peritoneal dialysis (PD) | 9946 ± 7858 6720 (3558; 14 595) | ||
Conservative treatment (CKD) | 8224 ± 7526 6123 (2854; 10 495) | ||
Before kidney transplant (TE A) | 11 331 ± 9872 6157 (5118; 14 013) | ||
After kidney transplant (TE B) | 9464 ± 8291 6057 (4320; 14 043) | ||
Control Group (NK) | 5658 ± 5264 4155 (347; 9675) | ||
Dopamine [ng/mL] | Before Hemodialysis (HD A) | 0,059 ± 0,114 0,022 (0,008; 0,05) | <0,001 |
After Hemodialysis (HD B) | 0,375 ± 1,424 0,091 (0,044; 0,19) | ||
Peritoneal dialysis (PD) | 0,008 ± 0,007 0,055 (0,04; 0,16) | ||
Conservative treatment (CKD) | 0,093 ± 0,107 0,076 (0,47; 0,11) | ||
Before kidney transplant (TE A) | 0,06 ± 0,038 0,051 (0,035; 0,09) | ||
After kidney transplant (TE B) | 0,077 ± 0,054 0,059 (0,037; 0,11) | ||
Control Group (NK) | 0,057 ± 0,036 0,05 (0,033; 0,072) | ||
Norepinephrine [nmol/L] | Before Hemodialysis (HD A) | 0,225 ± 0,583 0,015 (0,002; 0,05) | 0,002 |
After Hemodialysis (HD B) | 0,261 ± 0,298 0,149 (0,031; 0,36) | ||
Peritoneal dialysis (PD) | 0,396 ± 0,833 0,232 (0,004; 0,44) | ||
Conservative treatment (CKD) | 0,321 ± 0,518 0,228 (0,037; 0,34) | ||
Before kidney transplant (TE A) | 0,2 ± 0,166 0,187 (0,013; 0,34) | ||
After kidney transplant (TE B) | 0,517 ± 1,435 0,224 (0,037; 0,39) | ||
Control Group (NK) | 0,7 ± 1,935 0,135 (0,003; 0,436) |